Artificial Intelligence in Cancer Care Online Symposium

Chairs

Aleksandra Filipovic, UK - Dimitris Kalogeropoulos, UK

Date

25 May 2023

Background

Medicine is a practice that uses different sciences.

When managing serious, possibly life-threatening, diseases, we are constantly faced with two essential aspects of decision-making that appeal to what is important to treat the disease, on the one hand, and what is valuable to the person being treated, on the other. If artificial intelligence is applied to this valuable aspect, the amount of important information that can be gained for treating a disease today exceeds our capacity for immediate and integrative analysis. 

The integration of big data into clinical cancer research provides an unprecedented opportunity to integrate information and complex research outputs, which in turn requires powerful computational resources. Through its formidable analytical power, artificial intelligence holds the promise of transforming the way we study, diagnose and treat cancer.

The use of machine-learning in preclinical and translational cancer research has increased rapidly in recent years, bringing exciting progress in digital pathology and diagnostics and enriching foundational and drug-discovery research. From unfolding the intricacies of multi-omics and cellular phenotypes or extracting clinically relevant patterns to using behavioral data collected from wearable devices, machine learning is revolutionizing the arena of cancer research.

Artificial intelligence has given rise to great expectations for improving cancer diagnosis, prognosis and therapy but has also highlighted some of its inherent outstanding challenges, such as potential implicit biases in training datasets, data heterogeneity and the scarcity of external validation cohorts.

More information on the project and the seven webinars are available via www.spcc.net/artificial-intelligence-in-cancer-care

Learning Objectives

- To identify opportunities and challenges that may arise from the application of AI in Cancer Care Continuum

- To share best practices in the application of AI in cancer diagnosis and treatment

- To educate HCPs on the latest innovations of the application of AI to understand how it works on the clinical side

- To raise cancer patients' awareness of AI in cancer care

- To know implications of the new frontiers of AI in precision oncology

Target Group

HCPs - Cancer Patients Organisations – Oncologists - Researchers - Medical Companies - Cancer Institutes - Universities - Healthcare Public Authorities 

Course Format

The course will be held online with the participation of world-renowned experts, some of them already involved in webinars.

It will be free of charge and can be accessed by registering on SPCC's OncoCorner e-learning platform. The material will remain available on-demand.

Continuing Medical Education accreditation

Application for CME accreditation has been submitted to the Accreditation Council of Oncology in Europe (ACOE).

Participants will be issued a certificate of attendance (minimum attendance: 75% of the entire course). An online evaluation questionnaire and learning assessment test will need to be completed in order to get the certificate that will be issued by email.

Organising Secretariat

Sharing Progress in Cancer Care
Via Vincenzo Vela, 6
6500 Bellinzona – Switzerland

Martina Radice
martina.radice@spcc.net - Tel: +41 76 325 92 92

CME Accreditation and Certificates

Application for CME accreditation has been submitted to the Accreditation Council of Oncology in Europe (ACOE).

The programme was recognised as being of high quality from both a scientific and didactic point of view and was awarded 2 CME credits.
Participants will be issued a certificate of attendance (minimum attendance: 75% of the entire course). An online evaluation questionnaire and learning assessment test will need to be completed in order to get the certificate that will be issued by email.

Acknowledgements

Sharing Progress in Cancer Care wishes to express its appreciation to AstraZeneca, Novartis and Roche for their indipendent support.

Event attendance will be free of charge, but registration is required by Monday 23 May 2023.
Please register at https://www.oncocorner.net/online-events/52

INVITED FACULTY
Tim Chen, Foundation Medicine, Science Dept., Cambridge, US
Eduardo Farina, Federal University of São Paulo Unifesp, Radiology Dept., São Paulo, BR
Aleksandra Filipovic, Imperial College London, United Kingdom
Dimitris Kalogeropoulos, World Bank, European Commission, World Health Organization, UNICEF, Independent global health innovation adviser, London, UK
Dorothy Keefe, Cancer Australia, Management Dept., Surry Hills NSW, AU
Viktor Kölzer, University Hospital Zürich, Pathology Dept., Zürich, CH
Claudio Luchini, Verona University, Diagnostics and Public Health Dept - Section of Pathology, Verona, IT
Giancarlo Pruneri, NCI Milan Italy, Pathology Dept., Milano, IT
Pietro Valdastri, University of Leeds, Robotics and Autonomous Systems, Leeds, UK